oral picomolar & reversible CDK7 inhibitor
Ph. I candidate in breast cancer comb. Therapy
from previous CDK7 inhibitor SY-1365
Journal of Medicinal Chemistry
Syros Pharmaceuticals Inc.
4. The Syros Pharmaceuticals CDK7 kinase inhibitor, SY-5609, is a picomolar, reversible, and highly selective molecule with slow off-rate kinetics. It follows a prior covalent clinical candidate from Syros. The…